Transcriptome Signature Reversion as a Method to Reposition Drugs Against Cancer for Precision OncologyKoudijs, Karel K. M., PharmD*; Terwisscha van Scheltinga, Anton G. T., PharmD, PhD*; Böhringer, Stefan, MD, PhD†; Schimmel, Kirsten J. M., PharmD, PhD*; Guchelaar, Henk-Jan, PharmD, PhD†The Cancer Journal: March/April 2019 - Volume 25 - Issue 2 - p 116–120 doi: 10.1097/PPO.0000000000000370 Review Articles Buy SDC Abstract Author InformationAuthors Article MetricsMetrics Transcriptome signature reversion (TSR) has been hypothesized as a promising method for discovery and use of existing noncancer drugs as potential drugs in the treatment of cancer (i.e., drug repositioning, drug repurposing). The TSR assumes that drugs with the ability to revert the gene expression associated with a diseased state back to its healthy state are potentially therapeutic candidates for that disease. This article reviews methodology of TSR and critically discusses key TSR studies. In addition, potential conceptual and computational improvements of this novel methodology are discussed as well as its current and possible future application in precision oncology trials. From the Departments of *Clinical Pharmacy & Toxicology and †Medical Statistics, Leiden University Medical Centre, Leiden, the Netherlands. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Reprints: Henk-Jan Guchelaar, PharmD, PhD, Post-Office Box, 9600 2300 RC, Leiden Postzone L0-P, the Netherlands. E-mail: email@example.com. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.